HEADER ANTIBIOTIC 26-MAR-15 4Z0W TITLE PEPTAIBOL GICHIGAMIN ISOLATED FROM TOLYPOCLADIUM SUP_5 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEPTAIBOL GICHIGAMIN; COMPND 3 CHAIN: A, B SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: TOLYPOCLADIUM SP. SUP5 PDA-1; SOURCE 3 ORGANISM_TAXID: 1501327 KEYWDS PEPTAIBOL, ANTI-CANCER, TAIBOL, ANTIBIOTIC EXPDTA X-RAY DIFFRACTION AUTHOR L.DU,A.L.RISINGER,C.A.MITCHELL,B.W.STAMPS,N.PAN,J.B.KING,J.L.MOTLEY, AUTHOR 2 L.M.THOMAS,Z.YANG,B.S.STEVENSON,S.L.MOOBERRY,R.H.CICHEWICZ REVDAT 3 25-DEC-19 4Z0W 1 REMARK REVDAT 2 06-SEP-17 4Z0W 1 REMARK REVDAT 1 30-MAR-16 4Z0W 0 JRNL AUTH L.DU,A.L.RISINGER,C.A.MITCHELL,B.W.STAMPS,N.PAN,J.B.KING, JRNL AUTH 2 J.L.MOTLEY,L.M.THOMAS,Z.YANG,B.S.STEVENSON,S.L.MOOBERRY, JRNL AUTH 3 R.H.CICHEWICZ JRNL TITL PEPTAIBOL GICHIGAMIN ISOLATED FROM TOLYPOCLADIUM SUP_5 JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 25.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.110 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.121 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.250 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 749 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.130 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.145 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.240 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 604 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 11528 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 281 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 9 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 290.00 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 318.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 1 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 2623 REMARK 3 NUMBER OF RESTRAINTS : 2940 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.020 REMARK 3 ANGLE DISTANCES (A) : 0.041 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.020 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 1.049 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.079 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.031 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.009 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.093 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.004 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL.91(1973)201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4Z0W COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-APR-15. REMARK 100 THE DEPOSITION ID IS D_1000208412. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-AUG-14 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.542 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 14245 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.100 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 4.500 REMARK 200 R MERGE (I) : 0.10800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.2530 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.12 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : 4.00 REMARK 200 R MERGE FOR SHELL (I) : 0.29300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 5.412 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: AB INITIO REMARK 200 SOFTWARE USED: SHELX REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 17.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.48 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100% METHANOL, BATCH MODE, TEMPERATURE REMARK 280 295.65K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 GICHIGAMIN IS A LINEAR PEPTIDE, MEMBER OF THE PEPTAIBOL FAMILY OF REMARK 400 PEPTAIBIOTICS. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 23 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 BAL A 22 O REMARK 470 GLY B 23 O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 GLY B 23 C GLY B 23 OXT 0.181 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 BAL B 22 C - N - CA ANGL. DEV. = -19.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 AIB A 10 BAL A 11 144.97 REMARK 500 DIV A 13 BAL A 14 137.63 REMARK 500 AIB A 16 BAL A 17 140.54 REMARK 500 LEU A 21 BAL A 22 145.33 REMARK 500 AIB B 10 BAL B 11 143.15 REMARK 500 DIV B 13 BAL B 14 140.17 REMARK 500 AIB B 16 BAL B 17 140.96 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 PRO A 3 10.04 REMARK 500 PRO B 3 11.04 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1M24 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL TRICHOTOXIN_A50E REMARK 900 RELATED ID: 1R9U RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB IN METHANOL REMARK 900 RELATED ID: 1IH9 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB BOUND TO DPC REMARK 900 MICELLES REMARK 900 RELATED ID: 1GQ0 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL ANTIAMOEBIN I REMARK 900 RELATED ID: 1JOH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL ANTIAMOEBIN I REMARK 900 RELATED ID: 1AMT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL ALAMETHICIN REMARK 900 RELATED ID: 1EE7 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE PEPTAIBOL CHRYSOSPERMIN C BOUND TO DPC REMARK 900 MICELLES REMARK 900 RELATED ID: 1OB7 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL C REMARK 900 RELATED ID: 1OB6 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL B REMARK 900 RELATED ID: 1OB4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL A DBREF 4Z0W A 1 23 PDB 4Z0W 4Z0W 1 23 DBREF 4Z0W B 1 23 PDB 4Z0W 4Z0W 1 23 SEQRES 1 A 23 ACE AIB PRO AIB PRO PHE DIV PRO ALA AIB BAL ALA DIV SEQRES 2 A 23 BAL LEU AIB BAL LEU AIB AIB LEU BAL GLY SEQRES 1 B 23 ACE AIB PRO AIB PRO PHE DIV PRO ALA AIB BAL ALA DIV SEQRES 2 B 23 BAL LEU AIB BAL LEU AIB AIB LEU BAL GLY HET ACE A 1 6 HET AIB A 2 13 HET AIB A 4 13 HET DIV A 7 16 HET AIB A 10 13 HET BAL A 11 10 HET DIV A 13 16 HET BAL A 14 10 HET AIB A 16 13 HET BAL A 17 10 HET AIB A 19 13 HET AIB A 20 13 HET BAL A 22 9 HET ACE B 1 6 HET AIB B 2 13 HET AIB B 4 13 HET DIV B 7 16 HET AIB B 10 13 HET BAL B 11 10 HET DIV B 13 16 HET BAL B 14 10 HET AIB B 16 13 HET BAL B 17 10 HET AIB B 19 13 HET AIB B 20 13 HET BAL B 22 10 HETNAM ACE ACETYL GROUP HETNAM AIB ALPHA-AMINOISOBUTYRIC ACID HETNAM DIV D-ISOVALINE HETNAM BAL BETA-ALANINE FORMUL 1 ACE 2(C2 H4 O) FORMUL 1 AIB 12(C4 H9 N O2) FORMUL 1 DIV 4(C5 H11 N O2) FORMUL 1 BAL 8(C3 H7 N O2) FORMUL 3 HOH *9(H2 O) HELIX 1 AA1 PHE A 6 BAL A 22 5 17 HELIX 2 AA2 PHE B 6 BAL B 22 5 17 LINK C ACE A 1 N AIB A 2 1555 1555 1.34 LINK C AIB A 2 N PRO A 3 1555 1555 1.34 LINK C PRO A 3 N AIB A 4 1555 1555 1.36 LINK C AIB A 4 N PRO A 5 1555 1555 1.35 LINK C PHE A 6 N DIV A 7 1555 1555 1.33 LINK C DIV A 7 N PRO A 8 1555 1555 1.34 LINK C ALA A 9 N AIB A 10 1555 1555 1.33 LINK C AIB A 10 N BAL A 11 1555 1555 1.34 LINK C BAL A 11 N ALA A 12 1555 1555 1.32 LINK C ALA A 12 N DIV A 13 1555 1555 1.33 LINK C DIV A 13 N BAL A 14 1555 1555 1.33 LINK C BAL A 14 N LEU A 15 1555 1555 1.33 LINK C LEU A 15 N AIB A 16 1555 1555 1.33 LINK C AIB A 16 N BAL A 17 1555 1555 1.33 LINK C BAL A 17 N LEU A 18 1555 1555 1.31 LINK C LEU A 18 N AIB A 19 1555 1555 1.32 LINK C AIB A 19 N AIB A 20 1555 1555 1.33 LINK C AIB A 20 N LEU A 21 1555 1555 1.35 LINK C LEU A 21 N BAL A 22 1555 1555 1.34 LINK C ACE B 1 N AIB B 2 1555 1555 1.33 LINK C AIB B 2 N PRO B 3 1555 1555 1.32 LINK C PRO B 3 N AIB B 4 1555 1555 1.33 LINK C AIB B 4 N PRO B 5 1555 1555 1.34 LINK C PHE B 6 N DIV B 7 1555 1555 1.33 LINK C DIV B 7 N PRO B 8 1555 1555 1.34 LINK C ALA B 9 N AIB B 10 1555 1555 1.34 LINK C AIB B 10 N BAL B 11 1555 1555 1.33 LINK C BAL B 11 N ALA B 12 1555 1555 1.34 LINK C ALA B 12 N DIV B 13 1555 1555 1.34 LINK C DIV B 13 N BAL B 14 1555 1555 1.34 LINK C BAL B 14 N LEU B 15 1555 1555 1.33 LINK C LEU B 15 N AIB B 16 1555 1555 1.32 LINK C AIB B 16 N BAL B 17 1555 1555 1.35 LINK C BAL B 17 N LEU B 18 1555 1555 1.33 LINK C LEU B 18 N AIB B 19 1555 1555 1.34 LINK C AIB B 19 N AIB B 20 1555 1555 1.33 LINK C AIB B 20 N LEU B 21 1555 1555 1.32 LINK C LEU B 21 N BAL B 22 1555 1555 1.32 LINK C BAL B 22 N GLY B 23 1555 1555 1.33 CRYST1 10.065 18.791 31.424 75.16 88.54 86.48 P 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.099354 -0.006112 -0.001006 0.00000 SCALE2 0.000000 0.053318 -0.014068 0.00000 SCALE3 0.000000 0.000000 0.032923 0.00000 HETATM 1 C ACE A 1 8.637 2.337 -1.018 1.00 13.33 C ANISOU 1 C ACE A 1 2506 1490 943 60 41 -183 C HETATM 2 O ACE A 1 9.184 2.687 0.035 1.00 13.92 O ANISOU 2 O ACE A 1 2685 1431 1041 148 -82 -201 O HETATM 3 CH3 ACE A 1 7.957 0.963 -1.100 1.00 13.83 C ANISOU 3 CH3 ACE A 1 2538 1486 1102 61 47 -204 C HETATM 4 H1 ACE A 1 7.575 0.841 -1.995 1.00 20.75 H HETATM 5 H2 ACE A 1 8.618 0.260 -0.929 1.00 20.75 H HETATM 6 H3 ACE A 1 7.243 0.911 -0.431 1.00 20.75 H HETATM 7 N AIB A 2 8.587 3.116 -2.101 1.00 12.27 N ANISOU 7 N AIB A 2 2109 1547 891 -4 20 -209 N HETATM 8 CA AIB A 2 9.308 4.373 -2.199 1.00 11.92 C ANISOU 8 CA AIB A 2 1757 1479 1180 172 69 -157 C HETATM 9 C AIB A 2 9.056 5.276 -0.988 1.00 10.26 C ANISOU 9 C AIB A 2 1346 1341 1116 -15 109 -74 C HETATM 10 O AIB A 2 9.978 5.971 -0.587 1.00 11.58 O ANISOU 10 O AIB A 2 1464 1680 1147 -205 107 -68 O HETATM 11 CB1 AIB A 2 8.840 5.083 -3.463 1.00 12.46 C ANISOU 11 CB1 AIB A 2 1835 1570 1211 128 34 -108 C HETATM 12 CB2 AIB A 2 10.840 4.121 -2.263 1.00 14.88 C ANISOU 12 CB2 AIB A 2 1771 2014 1728 259 78 -303 C HETATM 13 H AIB A 2 8.098 2.856 -2.785 1.00 14.72 H HETATM 14 HB11 AIB A 2 9.313 5.937 -3.552 1.00 18.68 H HETATM 15 HB12 AIB A 2 9.031 4.521 -4.243 1.00 18.68 H HETATM 16 HB13 AIB A 2 7.876 5.248 -3.407 1.00 18.68 H HETATM 17 HB21 AIB A 2 11.309 4.979 -2.328 1.00 22.32 H HETATM 18 HB22 AIB A 2 11.128 3.653 -1.452 1.00 22.32 H HETATM 19 HB23 AIB A 2 11.049 3.574 -3.048 1.00 22.32 H